Who is Frances Arnold
Frances Hamilton Arnold is an American chemical engineer born on 25 July 1956 in Pittsburgh.[2] She received half the 2018 Chemistry Nobel for directed evolution of enzymes. George Smith and Gregory Winter shared the other half for a different method, phage display of peptides and antibodies.[25]
Education and interest in energy
She graduated in mechanical and aerospace engineering from Princeton in 1979 and earned her Berkeley chemical-engineering doctorate in 1985. Postdoctoral work followed in biophysical chemistry. Her training crossed engineering disciplines before focusing on proteins that catalyse chemical reactions.[8]
At Princeton she combined technical education with literature and philosophy. In an interview she recalled how broad learning helped her make connections relevant to evolution. Arriving during the university’s early coeducational years, she sought engineering skills while exploring her own interests.[10]
After graduation she worked at Colorado’s Solar Energy Research Institute. In 1980 she went to Berkeley to study biofuels with Harvey Blanch. Her interest in alternative energy developed into protein engineering as biotechnology began opening new manufacturing possibilities.[9]
Career and leadership at Caltech
She arrived at Caltech as a visiting associate in 1986 and joined its faculty in 1987, becoming associate professor in 1992 and professor in 1996. She has directed the Rosen Bioengineering Center since 2013 and held the Linus Pauling professorship in Chemical Engineering, Bioengineering and Biochemistry since 2017.[4]
Her laboratory researches directed evolution, synthetic biology and biocatalysis, seeking useful protein functions through experiments, design and data analysis. This combines the scientific question of how enzymes work with the engineering question of how to adapt them to a particular task.[1]
Developing directed evolution
In 1993, Keqin Chen and Arnold published a study of subtilisin E in the organic solvent dimethylformamide. Repeated variation and selection accumulated changes restoring catalytic activity in that environment. The results demonstrated useful properties without predicting each protein modification in advance.[11]
Variation, selection and experimentation
In her Nobel lecture she explained that a natural enzyme may perform poorly when given a different task. Directed evolution generates variants, measures their behaviour and retains those best meeting the chosen objective. Repeating these stages accumulates improvements that may individually be small.[12]
The observed improvements depended on the substrate and assay conditions, rather than establishing universal enzyme superiority.[11]
New reactions and applications
In 2016 she worked with Jennifer Kan, Russell Lewis and Kai Chen to adapt a cytochrome to form carbon–silicon bonds. The enzyme originated from Rhodothermus marinus. The study explored expanding biocatalysis beyond that protein’s customary functions.[13]
In 2024 her team and collaborators developed an enzyme capable of breaking carbon–silicon bonds in certain siloxanes. Caltech described a first step towards biodegradation. Translating this laboratory chemical capability into effective environmental processes requires further development and assessment.[14]
Work led experimentally by Ziqi Li and published in September 2026 developed an enzymatic route to chiral oxazolidinones used in antibiotics. The team sought improved selectivity and manufacturing. Caltech described a proof of concept whose industrial scaling and cost implications still required investigation.[15]
Connection with machine learning
With Kevin Yang and Zachary Wu, Arnold examined machine learning as a guide to directed evolution. Their work appeared as a 2018 preprint and in Nature Methods in 2019. Models learn from measured variants to propose promising sequences within a large space of possible combinations.[5]
Prediction and experimental validation
Another 2019 study evaluated machine learning with combinatorial protein libraries, including a GB1 dataset for comparing selection strategies. Experimental results inform which variants should be studied next, connecting computational prediction with laboratory measurement.[16]
Gevo, Provivi and Aralez Bio
Arnold cofounded Gevo in 2005 to develop fuels and chemicals from renewable resources.[8] In an entrepreneurship interview she stressed that commercialising a discovery requires skills beyond those of an academic inventor. Her ventures have drawn on specialised teams and former researchers.[17]
In 2013 she cofounded Provivi with Pedro Coelho and Peter Meinhold. It develops pheromones that disrupt insect mating to protect crops, connecting biotechnology production tools with pest management based on chemical signals. Use depends on the particular crop and product.[18]
In 2019 Tina Boville, David Romney and Arnold cofounded Aralez Bio from laboratory research. It uses enzymes to produce noncanonical amino acids, chemical building blocks expanding pharmaceutical-synthesis options. Boville described the transition from postdoctoral work to manufacturing and commercialising these compounds.[19]
Correction of the scientific record
In January 2020 Arnold, Inha Cho and Zhi-Jun Jia retracted a 2019 paper on enzymatic lactam synthesis.[20] Arnold publicly explained that the work could not be reproduced and apologised. The retraction concerns that particular study and forms part of her publication record.[21]
Awards and scientific advisory work
She was elected to the US national academies of Engineering in 2000, Medicine in 2004 and Sciences in 2008.[3] Her honours include the 2011 Draper Prize, the 2011 National Medal of Technology and Innovation, and the 2025 Priestley Medal, recognising connections between chemical discovery and process design.[24]
From 2021 to 2025 she cochaired the US President’s Council of Advisors on Science and Technology.[22] She serves on Alphabet’s board.[23] Notre Dame selected her for its 2026 Carrier Medal, associated with a lecture on innovation through evolution and new capabilities in biological chemistry.[26]
Biocatalysis, substance substitution and occupational exposure
Directed evolution developed by Arnold enables enzymes to be adapted to industrial reactions.[6] The Nobel scientific background places this contribution within the search for alternatives to processes that may use solvents, metals or aggressive acids.[6]
The occupational application lies in process design: changing a catalyst or manufacturing route can also change the agents handled by workers.
Assessing a particular substitution would require comparing the original and new processes: substances, temperature, open handling, cleaning and maintenance, alongside consumption and waste. The preventive question is not whether the enzyme performs better, but which exposures disappear and which emerge.
HSE lists certain enzymes among substances capable of causing occupational asthma.[7]
A powder formulation and a closed system therefore do not necessarily present the same scenario. Arnold’s contribution creates design options; demonstrating that a facility is safer requires examining its actual conditions. Improved catalytic performance alone does not establish reduced worker exposure, and biocatalysis should not automatically be treated as risk-free.
